{"id":"W4404406138","doi":"10.1016/j.ejca.2024.115122","title":"A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002611917,0.00009526897,0.0001334599,0.0001329838,0.00001917945,0.0000179092,0.00009693443,0.00001749846,0.00001840235],"category_scores_gemma":[0.00002527694,0.00007388715,0.00003667494,0.0001663032,0.00002570783,0.00001830721,0.00002701034,0.0001074155,8.123836e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003286476,"about_ca_system_score_gemma":0.00005226087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001099759,"about_ca_topic_score_gemma":0.0001352498,"domain_scores_codex":[0.9990525,0.0001121729,0.0004073881,0.0001348733,0.0001942124,0.00009887062],"domain_scores_gemma":[0.999552,0.00000434354,0.0001796211,0.0001013028,0.0001260613,0.0000366576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.004757291,0.004507851,0.4035422,0.0002695676,0.0003023627,0.000309544,0.004267651,0.007179377,0.4595283,0.00003807837,0.002261951,0.1130358],"study_design_scores_gemma":[0.02411607,0.01408427,0.8274704,0.001557252,0.00005595,0.000005698337,0.0006483213,0.00008835152,0.1102258,0.00001389594,0.02132918,0.0004047808],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982023,0.001031902,0.00007207,0.00005519098,0.0001806624,0.000197969,0.000005370761,0.000002974559,0.0002516033],"genre_scores_gemma":[0.9996082,0.00005003121,0.00006583099,0.00002159407,0.0001333236,0.000003579947,0.00000615298,0.00002009544,0.00009117498],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4239283,"threshold_uncertainty_score":0.301303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007978048884716541,"score_gpt":0.2706501542859294,"score_spread":0.2626721054012128,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}